CN110430893A - 用于癌症免疫疗法的新型的靶向pd-l1的dna疫苗 - Google Patents

用于癌症免疫疗法的新型的靶向pd-l1的dna疫苗 Download PDF

Info

Publication number
CN110430893A
CN110430893A CN201880018761.6A CN201880018761A CN110430893A CN 110430893 A CN110430893 A CN 110430893A CN 201880018761 A CN201880018761 A CN 201880018761A CN 110430893 A CN110430893 A CN 110430893A
Authority
CN
China
Prior art keywords
leu
ser
val
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880018761.6A
Other languages
English (en)
Chinese (zh)
Inventor
海因茨·卢本奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Si Meng Limited-Liability Co Of Wanke
Original Assignee
Si Meng Limited-Liability Co Of Wanke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Si Meng Limited-Liability Co Of Wanke filed Critical Si Meng Limited-Liability Co Of Wanke
Publication of CN110430893A publication Critical patent/CN110430893A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4562—Salmonella; Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880018761.6A 2017-03-17 2018-03-16 用于癌症免疫疗法的新型的靶向pd-l1的dna疫苗 Pending CN110430893A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17161666.7 2017-03-17
EP17161666 2017-03-17
EP17188941 2017-09-01
EP17188941.3 2017-09-01
PCT/EP2018/056721 WO2018167290A1 (en) 2017-03-17 2018-03-16 Novel pd-l1 targeting dna vaccine for cancer immunotherapy

Publications (1)

Publication Number Publication Date
CN110430893A true CN110430893A (zh) 2019-11-08

Family

ID=61627121

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880018761.6A Pending CN110430893A (zh) 2017-03-17 2018-03-16 用于癌症免疫疗法的新型的靶向pd-l1的dna疫苗

Country Status (13)

Country Link
US (2) US11357842B2 (https=)
EP (1) EP3595704A1 (https=)
JP (2) JP7247097B2 (https=)
KR (1) KR20190125481A (https=)
CN (1) CN110430893A (https=)
AU (1) AU2018235153A1 (https=)
BR (1) BR112019019251A2 (https=)
CA (1) CA3056807A1 (https=)
IL (1) IL268677A (https=)
MX (1) MX2019011026A (https=)
RU (1) RU2019132253A (https=)
SG (1) SG11201908528UA (https=)
WO (1) WO2018167290A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115645520A (zh) * 2022-11-15 2023-01-31 中国科学技术大学 一种化疗诱导的肿瘤蛋白抗原纳米疫苗的制备方法及其应用
CN118221773A (zh) * 2024-02-05 2024-06-21 首都医科大学附属北京儿童医院保定医院 与HLA相关的CMV pp65表位疫苗组合物与应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018101722A (ru) * 2015-06-18 2019-07-18 Факсимм Аг Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии
KR102851396B1 (ko) 2019-10-10 2025-08-26 주식회사 엘지에너지솔루션 히팅 패드 제어 장치
US20230121528A1 (en) 2020-01-13 2023-04-20 Vaximm Ag Salmonella-based dna vaccines in combination with an antibiotic
CU24705B1 (es) 2020-10-22 2024-06-11 Ct Ingenieria Genetica Biotecnologia Antígeno quimérico que comprende el dominio extracelular de pd-l1

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056716A1 (en) * 2011-10-17 2013-04-25 Herlev Hospital Pd-l1 based immunotherapy
US20150017194A1 (en) * 2013-07-12 2015-01-15 Vlp Therapeutics, Llc Virus like particle comprising pd-1 antigen or pd-1 ligand antigen
WO2015090584A1 (en) * 2013-12-18 2015-06-25 Vaximm Gmbh Mafinex-Technologiezentrum Novel msln targeting dna vaccine for cancer immunotherapy
CN105246496A (zh) * 2013-04-25 2016-01-13 万科斯蒙股份有限公司 用于癌症免疫治疗的靶向肾母细胞瘤基因wt-1的基于沙门菌的载体
CN106102771A (zh) * 2014-01-07 2016-11-09 巴比塔·阿格拉沃尔 免疫调节组合物及其使用方法
WO2016202459A1 (en) * 2015-06-18 2016-12-22 Vaximm Ag Vegfr-2 targeting dna vaccine for combination therapy
WO2016202458A1 (en) * 2015-06-18 2016-12-22 Vaximm Ag Novel cmv pp65 targeting dna vaccine for cancer immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584266B1 (en) * 1991-05-06 2003-09-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
JP6325534B2 (ja) 2012-07-05 2018-05-16 バクシム アクチェンゲゼルシャフト 膵臓癌患者用ｄｎａワクチン

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056716A1 (en) * 2011-10-17 2013-04-25 Herlev Hospital Pd-l1 based immunotherapy
CN105246496A (zh) * 2013-04-25 2016-01-13 万科斯蒙股份有限公司 用于癌症免疫治疗的靶向肾母细胞瘤基因wt-1的基于沙门菌的载体
US20160068801A1 (en) * 2013-04-25 2016-03-10 Vaximm Ag Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1
US20150017194A1 (en) * 2013-07-12 2015-01-15 Vlp Therapeutics, Llc Virus like particle comprising pd-1 antigen or pd-1 ligand antigen
WO2015090584A1 (en) * 2013-12-18 2015-06-25 Vaximm Gmbh Mafinex-Technologiezentrum Novel msln targeting dna vaccine for cancer immunotherapy
CN106061500A (zh) * 2013-12-18 2016-10-26 万科斯蒙股份有限公司 用于癌症免疫疗法的新颖的靶向msln的dna疫苗
CN106102771A (zh) * 2014-01-07 2016-11-09 巴比塔·阿格拉沃尔 免疫调节组合物及其使用方法
WO2016202459A1 (en) * 2015-06-18 2016-12-22 Vaximm Ag Vegfr-2 targeting dna vaccine for combination therapy
WO2016202458A1 (en) * 2015-06-18 2016-12-22 Vaximm Ag Novel cmv pp65 targeting dna vaccine for cancer immunotherapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREAS G NIETHAMMER等: "Double-blind, placebo-controlled first inhuman study to investigate an oral vaccineaimed to elicit an immune reaction against theVEGF-Receptor 2 in patients with stage IV andlocally advanced pancreatic cancer", 《BMC CANCER》 *
SHAMAILA MUNIR AHMAD等: "PD-L1 peptide co-stimulation increasesimmunogenicity of a dendritic cell-based cancervaccine", 《ONCOIMMUNOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115645520A (zh) * 2022-11-15 2023-01-31 中国科学技术大学 一种化疗诱导的肿瘤蛋白抗原纳米疫苗的制备方法及其应用
CN118221773A (zh) * 2024-02-05 2024-06-21 首都医科大学附属北京儿童医院保定医院 与HLA相关的CMV pp65表位疫苗组合物与应用

Also Published As

Publication number Publication date
WO2018167290A1 (en) 2018-09-20
KR20190125481A (ko) 2019-11-06
US20200085928A1 (en) 2020-03-19
MX2019011026A (es) 2020-12-10
US20220273782A1 (en) 2022-09-01
JP7247097B2 (ja) 2023-03-28
CA3056807A1 (en) 2018-09-20
AU2018235153A1 (en) 2019-10-31
BR112019019251A2 (pt) 2020-04-28
IL268677A (en) 2019-10-31
JP2023021116A (ja) 2023-02-09
US11357842B2 (en) 2022-06-14
EP3595704A1 (en) 2020-01-22
SG11201908528UA (en) 2019-10-30
JP2020511139A (ja) 2020-04-16
RU2019132253A (ru) 2021-04-19

Similar Documents

Publication Publication Date Title
KR102090612B1 (ko) 췌장암 환자용 dna 백신
CN110430893A (zh) 用于癌症免疫疗法的新型的靶向pd-l1的dna疫苗
AU2017295004B2 (en) Process for the production of a DNA vaccine for cancer immunotherapy
CN107995868B (zh) 用于联合治疗的vegfr-2靶向dna疫苗
AU2018222777B2 (en) Novel VEGFR-2 targeting immunotherapy approach
CN109906087A (zh) 用于联合治疗的wt1靶向dna疫苗
KR20210058825A (ko) 병용 요법용 신생항원 표적화 dna 백신
KR20220161444A (ko) 새로운 살모넬라-기반의 코로나바이러스 백신
KR20220128638A (ko) 항생제와 조합되는 살모넬라-기반의 dna 백신

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191108

WD01 Invention patent application deemed withdrawn after publication